The most effective strategy for managing distantly metastatic invasive carcinomas of the
cervix is not defined. Based on the success of niraparib in breast and ovarian cancer trials
and the concern for toxicities and comorbidities limiting the compliance of concurrent
cisplatin for cervical cancer, this study is a phase I/II study of women diagnosed with
distantly metastatic (Stage IV) disease to determine the maximum tolerated dose and to
evaluate the safety, tolerability and preliminary efficacy of niraparib, an orally available
small molecule PARP inhibitor when administered concurrently with definitive regional
radiotherapy for treatment of cervical cancer. Women enrolled in this study will receive 3-6
cycles of induction-style carboplatin and paclitaxel followed by definitive doses of pelvic
radiotherapy along with the oral niraparib given at the same time.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.